Quality of Life with Advanced Metastatic Prostate Cancer

被引：24

作者：

Resnick, Matthew J. ^{[1
,2
]}

Penson, David F. ^{[1
,2
]}

机构：

[1] Vanderbilt Univ, Dept Urol Surg, Ctr Surg Qual & Outcomes Res, Nashville, TN 37232 USA

[2] VA Tennessee Valley Geriatr Res Educ & Clin Ctr G, Nashville, TN 37212 USA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 04期

关键词：

Prostate cancer; Metastatic; Castrate-resistant; Quality of life; Functional status; Palliation; ANDROGEN-DEPRIVATION THERAPY; PAINFUL BONE METASTASES; SICKNESS IMPACT PROFILE; MITOXANTRONE PLUS PREDNISONE; HEALTH-STATUS; PHASE-II; RADIONUCLIDE TREATMENT; ASYMPTOMATIC MEN; RANDOMIZED-TRIAL; ZOLEDRONIC ACID;

D O I：

10.1016/j.ucl.2012.07.007

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The health-related quality-of-life (HRQOL) implications of advanced metastatic prostate cancer are variable. There are several different HRQOL instruments that measure domains germane to patients with advanced metastatic disease. The burden of prostate cancer is inversely related to the magnitude of HRQOL declines. Treatment with androgen deprivation therapy commonly results in HRQOL declines that have served as the impetus for intermittent therapy. Conversely, chemotherapeutic agents have been associated with improvements in functional status for men with castrate-resistant disease. Emerging therapies may result in significant HRQOL improvements in this population, and careful prospective evaluation of patient-reported outcomes will be required.

引用

页码：505 / +

页数：12

共 68 条

[51] Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
Saad, F
Gleason, DM
Murray, R
Tchekmedyian, S
Venner, P
Lacombe, L
Chin, JL
Vinholes, JJ
Goas, JA
Zheng, M
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) : 879 - 882
[52] Impact of Androgen Deprivation on Physical Well-Being in Patients With Prostate Cancer Analysis From the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) Registry
Sadetsky, Natalia
Greene, Kirsten
Cooperberg, Matthew R.
Hubbard, Alan
Carroll, Peter R.
Satariano, William
[J]. CANCER, 2011, 117 (19) : 4406 - 4413
[53] A population-based study of pain and quality of life during the year before death in men with prostate cancer
Sandblom, G
Carlsson, P
Sennfält, K
Varenhorst, E
[J]. BRITISH JOURNAL OF CANCER, 2004, 90 (06) : 1163 - 1168
[54] Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer
Sartor, O
Reid, RH
Hoskin, PJ
Quick, DP
Ell, PJ
Coleman, RE
Kotler, JA
Freeman, LM
Olivier, P
[J]. UROLOGY, 2004, 63 (05) : 940 - 945
[55] Schag C A, 1990, Oncology (Williston Park), V4, P135
[56] QUALITY-OF-LIFE IN ADULT SURVIVORS OF LUNG, COLON AND PROSTATE-CANCER
SCHAG, CAC
GANZ, PA
WING, DS
SIM, MS
LEE, JJ
[J]. QUALITY OF LIFE RESEARCH, 1994, 3 (02) : 127 - 141
[57] Cancer Statistics, 2012
Siegel, Rebecca
Naishadham, Deepa
Jemal, Ahmedin
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2012, 62 (01) : 10 - 29
[58] Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer
Spry, NA
Kristjanson, L
Hooton, B
Hayden, L
Neerhut, G
Gurney, H
Corica, T
Korbel, E
Weinstein, S
McCaul, K
[J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) : 1083 - 1092
[59] Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer
Sullivan, Patrick W.
Mulani, Parvez M.
Fishman, Mayer
Sleep, Darryl
[J]. QUALITY OF LIFE RESEARCH, 2007, 16 (04) : 571 - 575
[60] Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
Tannock, IF
Osoba, D
Stockler, MR
Ernst, DS
Neville, AJ
Moore, MJ
Armitage, GR
Wilson, JJ
Venner, PM
Coppin, CML
Murphy, KC
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1756 - 1764

← 1 2 3 4 5 6 7 →